Neurogene Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +6.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.40 | $-1.53 | -9.3% | Miss | |
| Q1 FY26 | $-1.35 | $-1.39 | -3.0% | Miss | |
| Q4 FY25 | $-1.20 | $-1.12 | +6.7% | Beat | |
| Q3 FY25 | $-1.26 | $-0.99 | +21.4% | Beat | |
| Q2 FY25 | $-1.15 | $-1.05 | +8.7% | Beat | |
| Q1 FY25 | $-1.05 | $-1.08 | -2.9% | Miss | |
| Q4 FY24 | $-1.04 | $-0.99 | +4.8% | Beat | |
| Q3 FY24 | $-1.23 | $-1.19 | +3.3% | Beat | |
| Q2 FY24 | $-1.02 | $-1.09 | -6.9% | Miss | |
| Q1 FY24 | not reported | $1.00 | not reported | not reported | |
| Q3 FY23 | $-0.80 | $-0.41 | +48.8% | Beat | |
| Q2 FY23 | not reported | $-0.04 | not reported | not reported |
Back to NGNE overview · NGNE holders · NGNE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.